Richard Stone Actinium Pharmaceuticals
Actinium Pharmaceuticals has appointed Richard Stone to its Scientific Advisory Board, to help develop payload immunotherapeutics for the treatment of advanced cancers.
Stone’s experience to date has focused on refractory leukaemia and advanced myeloproliferative disorders.
Actinium’s Scientific Advisory Board contributes to the development of Iomab-B, Actinium’s Phase III drug candidate, which is intended to facilitate bone marrow transports.
“I look forward to working with Dr. Stone at Actinium as we work to gain approval for Iomab-B for patients who lack effective methods of obtaining a potentially curative bone marrow transplant,” said Actinium’s chief medical officer Mark Berger.
Stone currently serves as Dana-Farber Cancer Institute’s Adult Leukaemia program director, professor of medicine at Harvard Medical School.
He is also on the Medical Oncology Board of the American Board of Internal Medicines, and vice chairs the Leukaemia Core Committee for the national cooperative trails group Cancer and Leukaemia Group B.